YY1 Asprosin PFKP Axis Identified as Key Regulator of Glycolysis in Pathological Cardiac Hypertrophy

A recent study published in *Nature Communications* has identified the YY1/Asprosin/PFKP axis as a critical factor in regulating glycolytic metabolism and contributing to pathological cardiac hypertrophy. The research highlights how this molecular pathway influences cardiac remodeling under stress, providing new insights into the mechanisms behind heart enlargement and dysfunction.

The findings reveal that the YY1 transcription factor interacts with Asprosin, a hormone involved in energy regulation, and PFKP, an enzyme central to glycolysis. Together, these components drive metabolic changes that exacerbate cardiac hypertrophy—a condition characterized by abnormal thickening of the heart muscle. The study underscores the role of this axis in promoting maladaptive responses during cardiovascular stress, offering potential targets for future therapeutic interventions aimed at mitigating heart disease progression.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 1, 2026

Author

GOAI